Singular Genomics Launches Spatial Genomics Initiative

- The initiative is centered around Singular's new G4X Spatial Sequencer, an instrument capable of analyzing 128 samples and 40 cm² of tissue per run. This represents a throughput nearly 10 times higher than other commercially available systems. The G4X has a list price of $495,000. - A key component of this initiative is the "Spatial Predictors of Tropism and Metastasis" (SPOT-Met) program, a collaboration with Weill Cornell Medicine. This program, led by Dr. Christopher Mason, will analyze 1,000 colorectal tumors to better understand metastatic behavior and therapy response. Dr. Mason is a professor of Genomics, Physiology, and Biophysics with extensive research in genomics and has co-founded four biotechnology startups. - The G4X platform offers multiomic capabilities, allowing for the simultaneous analysis of 500-plex RNA, 18-plex protein, and fluorescent H&E staining on the same tissue sample at subcellular resolution. An early access program for its "Direct-Seq" technology, for in-situ sequencing of RNA, is planned for the second half of 2026. - This strategic move into spatial genomics follows a period of financial restructuring for Singular Genomics (NASDAQ: OMIC). The company recently reduced its workforce by 20% to decrease operating expenses and extend its cash runway into late 2026. - The company's revenue for the fourth quarter of 2023 was $1.1 million, its highest quarterly total to date, though it still experienced a net loss of $23.2 million for the quarter. As of February 2026, the company's trailing twelve months revenue was $2.66 million. - The G4X positions Singular Genomics to compete with established players in the spatial biology market, such as 10x Genomics and their Xenium platform. Singular aims to differentiate by offering both next-generation sequencing (NGS) and spatial multiomics on a single instrument. - Prior to the G4X launch, Singular Genomics established partnerships with companies like Dovetail Genomics and Lexogen to integrate their library preparation assays with the G4 sequencer, indicating a strategy of creating a compatible ecosystem for its platforms. - The company has a history of collaborating with leading research institutions. An early access program for the G4X involved five academic medical centers, and the technology has already been used to process nearly 20,000 FFPE samples.